TY - JOUR
T1 - Outcomes of patients with rejection post-polyomavirus nephropathy
AU - Trofe, J.
AU - Roy-Chaudhury, P.
AU - Gordon, J.
AU - Wadih, G.
AU - Maru, D.
AU - Cardi, M. A.
AU - Succop, P.
AU - Alloway, R. R.
AU - Khalili, K.
AU - Woodle, E. S.
N1 - Funding Information:
This work was supported by The Paul Teschan Research Fund from Dialysis Clinics Incorporated for the 2003–2004 funding period awarded to Jennifer Trofe.
PY - 2005/3
Y1 - 2005/3
N2 - Introduction. We sought to determine the effects of rejection in renal transplant recipients with polyomavirus nephropathy (PVN). Methods. SCr, biopsy findings, BKV serum and urine loads (Taqman PCR), and BKV antibody titers (HA inhibition assay) were analyzed by two-sample median tests and z tests in 11 patients with median follow-up of 7.3 (2.0 to 31.5) months post-PVN. All patients underwent immunosuppression reduction (ISR) as PVN treatment. Results. Post-PVN, 3 (27%) patients had five rejection episodes, with 80% being mild. Median time to rejection was 18 (2 to 60) weeks. One hundred percent of patients who experienced post-PVN rejection also experienced rejection pre-PVN. Rejection episode treatments consisted of: none in one, increased tacrolimus in two, IVIG in one, IVIG and increased tacrolimus in one. Median viral loads in patients with post-PVN rejection versus those without rejection were not different in serum (2.01 × 104 vs 9.00 × 104 BKV copies/mL; P =. 22) or urine (5.37 × 105 vs 8.93 × 106 BKV copies/mL; P =. 28). Median BKV antibody titers were slightly lower (16384 vs 32768 HA units; P =. 02) and median SCr values were significantly higher (2.7 vs 1.9 mg/dL, P =. 0003) in patients who had experienced post-PVN rejection. Graft losses occurred in one rejection-free patient (chronic allograft nephropathy) and in one patient who experienced multiple acute rejection episodes, humoral rejection, and worsening PVN. Conclusions. Patients who experience rejection prior to PVN are at high risk of developing rejection post-ISR and post-PVN; however, low graft loss rates may still be achieved.
AB - Introduction. We sought to determine the effects of rejection in renal transplant recipients with polyomavirus nephropathy (PVN). Methods. SCr, biopsy findings, BKV serum and urine loads (Taqman PCR), and BKV antibody titers (HA inhibition assay) were analyzed by two-sample median tests and z tests in 11 patients with median follow-up of 7.3 (2.0 to 31.5) months post-PVN. All patients underwent immunosuppression reduction (ISR) as PVN treatment. Results. Post-PVN, 3 (27%) patients had five rejection episodes, with 80% being mild. Median time to rejection was 18 (2 to 60) weeks. One hundred percent of patients who experienced post-PVN rejection also experienced rejection pre-PVN. Rejection episode treatments consisted of: none in one, increased tacrolimus in two, IVIG in one, IVIG and increased tacrolimus in one. Median viral loads in patients with post-PVN rejection versus those without rejection were not different in serum (2.01 × 104 vs 9.00 × 104 BKV copies/mL; P =. 22) or urine (5.37 × 105 vs 8.93 × 106 BKV copies/mL; P =. 28). Median BKV antibody titers were slightly lower (16384 vs 32768 HA units; P =. 02) and median SCr values were significantly higher (2.7 vs 1.9 mg/dL, P =. 0003) in patients who had experienced post-PVN rejection. Graft losses occurred in one rejection-free patient (chronic allograft nephropathy) and in one patient who experienced multiple acute rejection episodes, humoral rejection, and worsening PVN. Conclusions. Patients who experience rejection prior to PVN are at high risk of developing rejection post-ISR and post-PVN; however, low graft loss rates may still be achieved.
UR - http://www.scopus.com/inward/record.url?scp=17844398534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17844398534&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2004.12.098
DO - 10.1016/j.transproceed.2004.12.098
M3 - Article
C2 - 15848582
AN - SCOPUS:17844398534
SN - 0041-1345
VL - 37
SP - 942
EP - 944
JO - Transplantation proceedings
JF - Transplantation proceedings
IS - 2
ER -